文献速递眼底病与葡萄膜炎

质子及重离子放疗葡萄膜黑色素瘤的疗效分析

[Analysis of therapeutic effects of proton and heavy ion radiotherapy on uveal melanoma].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2026-01-01

该回顾性病例系列研究纳入69例葡萄膜黑色素瘤患者,分别接受质子或重离子放疗。放疗后肿瘤最大基底直径和厚度均显著缩小(均P<0.05),局部控制率98.6%,5年累积保眼率90.6%,3年和5年累积无转移生存率分别为93.7%和90.3%。

要点

  • 质子及重离子放疗葡萄膜黑色素瘤局部控制率达98.6%,5年累积保眼率90.6%。
  • 放疗后肿瘤最大基底直径和厚度均较放疗前显著减小(均P<0.05)。
  • 主要并发症包括放射性视网膜病变42.0%、黄斑水肿37.7%、视网膜脱离34.8%、白内障33.3%。

核心结论

  • 质子及重离子放疗葡萄膜黑色素瘤局部控制率和保眼率高,安全性较好,且可保留部分视力。

研究设计与样本

  • 回顾性病例系列研究,纳入2015至2020年于国外行质子放疗及2020年7月至2025年8月行重离子放疗的葡萄膜黑色素瘤患者共69例(69只眼)。

主要发现

  • 肿瘤最大基底直径从基线(11.3±2.9)mm降至放疗后(9.5±3.5)mm,肿瘤厚度从(6.7±2.3)mm降至(5.5±2.7)mm,差异均有统计学意义(均P<0.05)。
  • 放疗后19例患者最佳矫正视力≥0.1。
  • 4例(5.8%)行眼球摘除术,其中3例因新生血管性青光眼,1例因肿瘤局部切除术后前房种植复发。
  • 4例患者肿瘤肝转移,1例乳腺转移,3年和5年累积无转移生存率分别为93.7%和90.3%。

关键数值与推荐

  • 肿瘤局部控制率为98.6%(68/69)。
  • 5年累积保眼率为90.6%。
  • 主要并发症:放射性视网膜病变29/69(42.0%)、黄斑水肿26/69(37.7%)、视网膜脱离24/69(34.8%)、白内障23/69(33.3%)。

临床怎么用

  • 质子及重离子放疗可作为葡萄膜黑色素瘤的有效治疗选择,有助于局部控制、保眼及保留部分视力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effectiveness and prognosis of uveal melanoma treated with proton or heavy ion therapy. Methods: A retrospective analysis was performed. We enrolled patients diagnosed with uveal melanoma at the Department of Ophthalmology, Eye & ENT Hospital of Fudan University between 2015 and 2020 and receiving proton beam therapy overseas, as well as patients diagnosed with uveal melanoma and treated with heavy ion radiotherapy at the Department of Ophthalmology, Eye & ENT Hospital of Fudan University and the Department of Radiotherapy, Shanghai Proton and Heavy Ion Center from July 2020 to August 2025. Patients' information was collected, including the gender, age, best-corrected visual acuity and its changes, largest basal diameter and thickness of the tumor and their changes, tumor stage, radiotherapy type and complications, supplementary treatments after radiotherapy, and follow-up duration and modalities. The t-test was used to compare the changes in tumor diameter and thickness before and after radiotherapy. The local control rate of the tumor was summarized. Survival curves were drawn. The Kaplan-Meier product-limit method was used to calculate the cumulative metastasis-free survival rate and cumulative eye preservation rate at 3 and 5 years. Results: A total of 69 patients (69 eyes) were included. There were 31 males (44.9%) and 38 females (55.1%), with an average age of (46.5±12.2) years. The tumor stage (tumor-lymph node-distant metastasis staging system) was mainly T2 (33/69, 47.8%) and T3 stage (23/69, 33.3%). Twelve patients (17.4%) received proton radiotherapy, and 57 patients (82.6%) received heavy ion radiotherapy. The follow-up, which was conducted through outpatient visits and telephone interviews, lasted (40.2±31.8) months. The largest basal diameter of the tumor significantly decreased from (11.3±2.9) mm at baseline to (9.5±3.5) mm after radiotherapy, and the tumor thickness was reduced from (6.7±2.3) mm to (5.5±2.7) mm; both were statistically significant (both P<0.05). After treatment, 19 patients retained best-corrected visual acuity of≥0.1, and the major complications were radiation-induced retinopathy (29/69, 42.0%), macular edema (26/69, 37.7%), retinal detachment (24/69, 34.8%), and cataracts (23/69, 33.3%). Four patients (5.8%) ultimately underwent enucleation, including three cases due to neovascular glaucoma, and one case of anterior chamber seeding recurrence after local tumor resection. The local tumor control rate was 98.6% (68/69), and the 5-year cumulative eye preservation rate was 90.6%. In terms of survival prognosis, four patients had liver metastasis of the tumor, one patient had breast metastasis, and the 3-and 5-year cumulative metastasis-free survival rates were 93.7% and 90.3%, respectively. Conclusion: Both proton radiotherapy and heavy ion radiotherapy for uveal melanoma not only achieve high local tumor control and eye preservation rates with a favorable safety profile, but also help to preserve partial visual acuity, holding promising prospects. 目的: 探讨质子及重离子放射治疗(放疗)葡萄膜黑色素瘤的预后情况。 方法: 回顾性病例系列研究。收集2015至2020年在复旦大学附属眼耳鼻喉科医院眼科确诊并于国外行质子放疗,以及2020年7月至2025年8月在复旦大学附属眼耳鼻喉科医院眼科和上海市质子重离子医院放疗科确诊并进行重离子放疗的葡萄膜黑色素瘤患者资料,包括患者的性别、年龄、最佳矫正视力(BCVA)及其变化情况、肿瘤最大基底直径和肿瘤厚度及其变化情况、肿瘤分期、放疗类型和并发症、放疗后补充治疗、随访时间和方式等。采用t检验比较放疗前后肿瘤直径和厚度变化,总结肿瘤局部控制率,绘制生存曲线,使用Kaplan-Meier乘积极限法计算3和5年累积无转移生存率、累积保眼率等。 结果: 共纳入69例患者(69只眼),男性31例(44.9%),女性38例(55.1%),年龄为(46.5±12.2)岁。肿瘤分期(肿瘤-淋巴结-远处转移分期系统)主要为T2(33/69,47.8%)和T3期(23/69,33.3%);12例患者(17.4%)行质子放疗,57例患者(82.6%)行重离子放疗。门诊和电话随访时间为(40.2±31.8)个月。肿瘤最大基底直径放疗后[(9.5±3.5)mm]与放疗前[(11.3±2.9)mm]比较,肿瘤厚度放疗后[(5.5±2.7)mm]与放疗前[(6.7±2.3)mm]比较,差异均有统计学意义(均P<0.05)。放疗后19例患者BCVA≥0.1,主要放疗并发症为放射性视网膜病变(29/69,42.0%)、黄斑水肿(26/69,37.7%)、视网膜脱离(24/69,34.8%)、白内障(23/69,33.3%)。4例患者(5.8%)行眼球摘除术,其中3例因新生血管性青光眼,1例因肿瘤局部切除术后前房种植复发。肿瘤局部控制率为98.6%(68/69),5年累积保眼率为90.6%。4例患者肿瘤肝部转移,1例患者乳腺转移,3年、5年累积无转移生存率分别为93.7%、90.3%。 结论: 质子及重离子放疗葡萄膜黑色素瘤,局部控制率和保眼率高,安全性较好,且可保留部分视力,具有良好的应用前景。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yue H, Kong L, Hu WX, et al. [Analysis of therapeutic effects of proton and heavy ion radiotherapy on uveal melanoma]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 42706143. doi:10.3760/cma.j.cn112142-20251212-00527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。